Differences Identified According to Ejection Fraction in Heart Failure
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
THURSDAY, July 20, 2023 -- Patients with acute decompensated heart failure (ADHF) have significant differences according to left ventricular ejection fraction, according to a study recently published in BMC Cardiovascular Disorders.
Ming-Shyan Lin, from Chang Gung Memorial Hospital Chiayi Branch in Taiwan, and colleagues conducted a retrospective cohort study between 2001 and 2021 involving ADHF patients discharged from hospitals. The primary outcome components were cardiovascular mortality and heart failure rehospitalizations, as well as all-cause mortality, acute myocardial infarction (AMI), and stroke.
A total of 12,852 ADHF patients were identified, including 17.3 percent with heart failure with mildly reduced ejection fraction (HFmrEF). The researchers found that patients with HFmrEF had a significant phenotype comorbid with diabetes, dyslipidemia, and ischemic heart disease in comparison with patients with heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF). Similar rates of cardioversion and coronary interventions were seen for both HFmrEF and HFrEF. An intermediate clinical outcome was seen between HFpEF and HFrEF; the highest rate of AMI was seen with HFmrEF (9.3, 13.6, and 9.9 percent for HFpEF, HFmrEF, and HFrEF, respectively). The AMI rates were significantly higher in HFmrEF than HFpEF but not HFrEF.
"These findings are of importance to future research strategies on prevention and treatment of different HF types and ischemic heart disease," the authors write.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted July 2023
Read this next
Gains in Heart Failure Mortality Have Been Erased
FRIDAY, April 26, 2024 -- Declines in heart failure-related mortality from 1999 to 2012 were entirely reversed from 2012 to 2021, according to a research letter published online...
Reports of Injuries, Deaths Prompt FDA to Recall Heart Failure Devices
WEDNESDAY, April 17, 2024 -- The HeartMate II and HeartMate 3, manufactured by Thoratec Corp., a subsidiary of Abbott Laboratories, are now under a strict U.S. Food and Drug...
American College of Cardiology, April 6 to 8
The annual meeting of the American College of Cardiology was held from April 6 to 8 in Atlanta and attracted more than 12,000 participants, including clinicians, academicians...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.